S. Mudivarthy

Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study

Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease et al. · Arthritis & Rheumatism · 2009 · 603 citations

Medicine, Clinical Sciences, Pharmacotherapy +15

Golimumab in psoriatic arthritis: One‐year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo‐controlled trial

Arthur Kavanaugh, Désirée van der Heijde, Iain B. McInnes et al. · Arthritis & Rheumatism · 2012 · 209 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14

Clinical efficacy, radiographic and safety findings through 2 years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study

Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease et al. · Annals of the Rheumatic Diseases · 2012 · 92 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +15